Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial

Danijela Golo, Jasna But-Hadzic, Franc Anderluh, Erik Brecelj, Ibrahim Edhemovic, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Secerov-Ermenc, Vaneja Velenik, Danijela Golo, Jasna But-Hadzic, Franc Anderluh, Erik Brecelj, Ibrahim Edhemovic, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Secerov-Ermenc, Vaneja Velenik

Abstract

Background The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G ≥ 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89-64.11) and 69.5% (95% CI 69.39-69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.

Keywords: neoadjuvant chemotherapy; pathologic complete response; preoperative chemoradiotherapy; rectal cancer; total neoadjuvant therapy.

Figures

Figure 1
Figure 1
Distribution of patients through the trial.
Figure 2
Figure 2
Prognostic significance of pathologic nodal stage (pN) and pathologic tumour stage (pT) in 5-year disease free survival and overall survival in rectal cancer after preoperative chemoradiotherapy and surgery. Time (m = months).

References

    1. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L. et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7. doi: 10.1016/S1470-2045(14)71199-4.
    1. Martin ST, Heneghan HM, Winter DC.. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28. doi: 10.1002/bjs.8702.
    1. Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A. et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19:2822–32. doi: 10.1245/s10434-011-2209-y.
    1. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B.. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006;47:693–700.
    1. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL. et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65. doi: 10.1200/JCO.2012.42.8771.
    1. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 Randomized Phase III Trial. J Clin Oncol. 2011;29:2773–80. doi: 10.1200/JCO.2010.34.4911.
    1. Edge SB, Compton CC.. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4. doi: 10.1245/s10434-010-09854.
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common terminology criteria for adverse events v4.0 (CTCAE). 2009;2009:0–71. Publish. Available at.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–56.
    1. Fleming TR.. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–51.
    1. A’Hern RP.. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20:859–66. doi: 10.1002/sim.721.
    1. Velenik V, Oblak I, Anderluh F.. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol. 2010;5:88. doi: 10.1186/1748-717X-5-88.
    1. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B. et al. Phase II. randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65. doi: 10.1200/JCO.2009.25.8541.
    1. Marechal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P. et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525–30. doi: 10.1093/annonc/mdr473.
    1. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A. et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) J Clin Oncol. 2012;30:1620–7. doi: 10.1200/JCO.2011.39.6036.
    1. Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B. et al. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C Trial. Int J Radiat Oncol. 2015;93:303–12. doi: 10.1016/j.ijrobp.2015.03.038.
    1. Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C. et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016;27:1557–65. doi: 10.1093/annonc/mdw215.
    1. Teo MTW, McParland L, Appelt AL. Sebag-Montefiore D. Phase 2 neoadjuvant treatment intensification trials in rectal cancer: a systematic review. Int J Radiat Oncol. 2018;100:146–58. doi: 10.1016/j.ijrobp.2017.09.042.
    1. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C. et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62. doi: 10.1200/JCO.2013.54.3769.
    1. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM.. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011;305 doi: 10.1001/jama.2011.749. 2335.
    1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23. doi: 10.1056/NEJMoa060829.
    1. Perez K, Safran H, Sikov W, Vrees M, Klipfel A, Shah N. et al. Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE Study. Am J Clin Oncol. 2017;40:283–7. doi: 10.1097/COC.0000000000000149.
    1. Nogue M, Salud A, Vicente P, Arrivi A, Roca JM, Losa F. et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS Study. Oncologist. 2011;16:614–20. doi: 10.1634/theoncologist.2010-0285.
    1. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S. et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. doi: 10.1200/JCO.2013.53.7753.
    1. Schou J V, Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E. et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol. 2012;23:2627–33. doi: 10.1093/annonc/mds056.
    1. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C. et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26:1722–8. doi: 10.1093/annonc/mdv223.
    1. Zampino MG, Magni E, Leonardi MC, Petazzi E, Santoro L, Luca F. et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75:421–7. doi: 10.1016/j.ijrobp.2008.11.002.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する